Churg-Strauss syndrome: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "5 mg" to "5mg") |
Neil.m.young (talk | contribs) (Text replacement - "==Diagnosis==" to "==Evaluation==") |
||
| Line 23: | Line 23: | ||
*Other vasculitides | *Other vasculitides | ||
== | ==Evaluation== | ||
*Typically a clinical diagnosis | *Typically a clinical diagnosis | ||
*Labs with elevated eosinophils, ESR, CRP, ANCA | *Labs with elevated eosinophils, ESR, CRP, ANCA | ||
Revision as of 07:27, 22 July 2016
Background
- Eosinophilic granulomatosis with polyangiitis (EGPA)
- Chronic sinusitis, asthma, and peripheral eosinophilia
- Vasculitis of small and medium sized vessels
- Lung and skin are most commonly involved
Clinical Features
Classically develops in three sequential phases:
- Prodrome
- Atopic diseases, allergic rhinitis, and asthma
- Eosinophilic phase
- Multiorgan involvement, particularly lung and GI tract
- Caused by eosinophilic infiltration into these organs
- Vasculitic phase
- Life threatening vasculitis associated with vascular and extravascular granulomatosis
- May present with nonspecific signs such as fever, weight loss, malaise
Differential Diagnosis
- Aspirin-exacerbated respiratory disease
- Chronic eosinophilic pneumonia
- Allergic bronchopulmonary aspergillosis
- Hypereosinophilic syndrome
- Other vasculitides
Evaluation
- Typically a clinical diagnosis
- Labs with elevated eosinophils, ESR, CRP, ANCA
- CXR with transient, patchy opacities
Management
Initiation Therapy
- Prednisone 0.5-1.5mg/kg/day
- Cyclophosphamide
Maintenance Therapy
- Azathioprine
- Methotrexate
- Leflunomide
- Inhaled glucocorticoids
Disposition
- Refer to rheumatology